235 related articles for article (PubMed ID: 31655267)
1. Neuromyelitis optica spectrum disorder after treatment with pembrolizumab.
Shimada T; Hoshino Y; Tsunemi T; Hattori A; Nakagawa E; Yokoyama K; Hattori N
Mult Scler Relat Disord; 2020 Jan; 37():101447. PubMed ID: 31655267
[TBL] [Abstract][Full Text] [Related]
2. A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study.
Hirano S; Kojima A; Nakayama Y; Takeda T; Kishimoto T; Takahashi T; Kuwabara S; Mori M
BMC Neurol; 2022 Dec; 22(1):483. PubMed ID: 36517738
[TBL] [Abstract][Full Text] [Related]
3. Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
Pardo S; Giovannoni G; Hawkes C; Lechner-Scott J; Waubant E; Levy M
Mult Scler Relat Disord; 2019 Aug; 33():A1-A2. PubMed ID: 31324299
[No Abstract] [Full Text] [Related]
4. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report.
Narumi Y; Yoshida R; Minami Y; Yamamoto Y; Takeguchi S; Kano K; Takahashi K; Saito T; Sawada J; Terui H; Katayama T; Sasaki T; Ohsaki Y
BMC Cancer; 2018 Jan; 18(1):95. PubMed ID: 29361915
[TBL] [Abstract][Full Text] [Related]
5. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
[TBL] [Abstract][Full Text] [Related]
6. Two Cases of Pediatric AQP4-Antibody Positive Neuromyelitis Optica Spectrum Disorder Successfully Treated with Tocilizumab.
Breu M; Glatter S; Höftberger R; Freilinger M; Kircher K; Kasprian G; Seidl R; Kornek B
Neuropediatrics; 2019 Jun; 50(3):193-196. PubMed ID: 30913570
[TBL] [Abstract][Full Text] [Related]
7. AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review.
Tao S; Zhang Y; Ye H; Guo D
Mult Scler Relat Disord; 2019 Oct; 35():185-192. PubMed ID: 31398657
[TBL] [Abstract][Full Text] [Related]
8. Neuromyelitis Optica Spectrum Disorder with Recurrent Intracranial Hemorrhage.
Yaguchi H; Mito Y; Ohashi I; Nomura T; Yabe I; Tajima Y
Intern Med; 2017; 56(13):1729-1732. PubMed ID: 28674367
[TBL] [Abstract][Full Text] [Related]
9. Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab.
Shidahara K; Hayashi K; Sada KE; Hiramatsu S; Morishita M; Watanabe H; Matsumoto Y; Kawabata T; Wada J
Lupus; 2018 Jul; 27(8):1374-1377. PubMed ID: 29498304
[TBL] [Abstract][Full Text] [Related]
10. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.
Ahn SH; Kim SM; Sung JJ
Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297
[TBL] [Abstract][Full Text] [Related]
11. Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.
Cotzomi E; Stathopoulos P; Lee CS; Ritchie AM; Soltys JN; Delmotte FR; Oe T; Sng J; Jiang R; Ma AK; Vander Heiden JA; Kleinstein SH; Levy M; Bennett JL; Meffre E; O'Connor KC
Brain; 2019 Jun; 142(6):1598-1615. PubMed ID: 31056665
[TBL] [Abstract][Full Text] [Related]
12. Inebilizumab for treatment of neuromyelitis optica spectrum disorder.
J Tullman M; Zabeti A; Vuocolo S; Dinh Q
Neurodegener Dis Manag; 2021 Oct; 11(5):341-352. PubMed ID: 34486379
[TBL] [Abstract][Full Text] [Related]
13. Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis optica spectrum disorder.
Creed MA; Ballesteros E; Jr LJG; Imitola J
Mult Scler Relat Disord; 2020 Sep; 44():102199. PubMed ID: 32554285
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders.
Duchow A; Paul F; Bellmann-Strobl J
Expert Opin Biol Ther; 2020 Sep; 20(9):1061-1072. PubMed ID: 32228250
[TBL] [Abstract][Full Text] [Related]
15. Presence of anti-Ro/SSA antibody may be associated with anti-aquaporin-4 antibody positivity in neuromyelitis optica spectrum disorder.
Park JH; Hwang J; Min JH; Kim BJ; Kang ES; Lee KH
J Neurol Sci; 2015 Jan; 348(1-2):132-5. PubMed ID: 25500159
[TBL] [Abstract][Full Text] [Related]
16. Inebilizumab: First Approval.
Frampton JE
Drugs; 2020 Aug; 80(12):1259-1264. PubMed ID: 32729016
[TBL] [Abstract][Full Text] [Related]
17. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.
Wu Y; Zhong L; Geng J
Mult Scler Relat Disord; 2019 Jan; 27():412-418. PubMed ID: 30530071
[TBL] [Abstract][Full Text] [Related]
18. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies.
Sepúlveda M; Sola-Valls N; Escudero D; Rojc B; Barón M; Hernández-Echebarría L; Gómez B; Dalmau J; Saiz A; Graus F
Mult Scler; 2018 Nov; 24(13):1753-1759. PubMed ID: 28920766
[TBL] [Abstract][Full Text] [Related]
19. Aquaporin-4-antibody-positive Neuromyelitis Optica Spectrum Disorder in a Patient with Charcot-Marie-Tooth Disease Type 1A.
Hamada Y; Takahashi K; Kanbayashi T; Hatanaka Y; Kobayashi S; Sonoo M
Intern Med; 2021 May; 60(10):1611-1614. PubMed ID: 33361678
[TBL] [Abstract][Full Text] [Related]
20. Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder.
Siebert N; Duchow A; Paul F; Infante-Duarte C; Bellmann-Strobl J
Drugs Today (Barc); 2021 May; 57(5):321-336. PubMed ID: 34061127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
